Recent Updates
Recently added Catalysts
USNA Neutral Sentiment

USANA Health Sciences Reports First Quarter 2026 Results

Key Takeaway: USANA Health Sciences has released its financial results for the first quarter of 2026. The report includes key performance metrics and insights into the company's operations. However, specific details regarding revenue, profit margins, or strategic initiatives were not provided in the article.
Price reaction · baseline $18.56 (2026-05-04 close) · hit after-hours · 1 other USNA headline(s) in the window, move may be shared
day 0 close · peak
+3.8%

Market Sentiment Analysis

Full Press Release Details

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 4, 2026.

Key Financial Results

First Quarter 2026 vs. First Quarter 2025

• Net sales of $250 million versus $250 million.
• Net earnings of $7.5 million versus $9.4 million.
• Diluted EPS of $0.41 as compared with $0.49.
• Adjusted diluted EPS(1)of $0.61 as compared with $0.73.
• Adjusted EBITDA(2)of $28.4 million versus $29.8 million.
• Core Nutritional Active Customers of 404,000 versus 459,000.
• Hiya Active Monthly Subscribers of 186,000 versus 224,000.
• Company reiterates fiscal 2026 guidance.

Q1 2026 Consolidated Performance

Q1 2026 Year-Over-Year Sequentially
Net Sales $250 million Flat (+$8 million or +3% FX impact) +11%
Net Earnings $7.5 million -20% N/A
Diluted EPS $0.41 -16% N/A
Adjusted Diluted EPS(1) $0.61 -16% +2%
Adjusted EBITDA(2) $28.4 million -5% +4%

Q1 2026

Year-Over-Year

Sequentially

Net Sales

$250 million
Flat (+$8 million or +3% FX impact)
+11%

Net Earnings

$7.5 million
-20%
N/A

Diluted EPS

$0.41
-16%
N/A

Adjusted Diluted EPS(1)

$0.61
-16%
+2%

Adjusted EBITDA(2)

$28.4 million
-5%
+4%
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.
“Our first quarter 2026 results reflect USANA’s continued evolution from a single-channel direct sales business to a diversified, omnichannel health and wellness enterprise," said Kevin Guest, Chairman and Chief Executive Officer. "Our omnichannel platform is intended to provide multiple growth engines, and early progress across our three segments reinforces confidence that our strategy will deliver sustained incremental value over time. The Core Nutritional business delivered solid sequential improvement during the quarter, driven by growth in total active customers in China in addition to continued focus on accelerating our new product launch initiatives. Meanwhile, Hiya established the operational foundation for a meaningfully stronger second half of the year and Rise Wellness generated triple-digit growth as Protein Pop hit Costco shelves nationwide.
“As we look ahead, the investments we are making today in product innovation, brand building, channel expansion, and technology modernization reinforce confidence in our strategic direction. These investments position us to compete effectively across the full spectrum of health-conscious consumer shopping preferences. We are committed to advancing our omnichannel strategy with urgency and discipline."

Q1 2026 Segment Results

Core Nutritional

Core Nutritional
Q1 2026 Year-Over-Year Sequentially
Net Sales $204 million -3% +7%
Active Customers 404,000 -12% +4%

Core Nutritional

Q1 2026

Year-Over-Year

Sequentially

Net Sales

$204 million
-3%
+7%

Active Customers

404,000
-12%
+4%
Asia Pacific Region
Q1 2026 Year-Over-Year Year-Over-Year(Constant Currency) Sequentially
Net Sales $169 million -2% -6% +12%
Active Customers 326,000 -13% N/A +7%

Asia Pacific Region

Q1 2026

Year-Over-Year

Year-Over-Year(Constant Currency)

Sequentially

Net Sales

$169 million
-2%
-6%
+12%

Active Customers

326,000
-13%
N/A
+7%
Asia Pacific Sub-Regions
Q1 2026 Year-Over-Year Year-Over-Year(Constant Currency) Sequentially
Greater China Net Sales $123 million +4% Flat +23%
Active 235,000 -7% N/A +13%
Customers
North Asia Net Sales $15 million -19% -18% -9%
Active 32,000 -29% N/A -9%
Customers
Southeast Asia Pacific Net Sales $31 million -14% -20% -10%
Active 59,000 -21% N/A -6%
Customers

Asia Pacific Sub-Regions

Q1 2026

Year-Over-Year

Year-Over-Year(Constant Currency)

Sequentially

Greater China

Net Sales

$123 million
+4%
Flat
+23%

Active

235,000
-7%
N/A
+13%

Customers

North Asia

Net Sales

$15 million
-19%
-18%
-9%

Active

32,000
-29%
N/A
-9%

Customers

Southeast Asia Pacific

Net Sales

$31 million
-14%
-20%
-10%

Active

59,000
-21%
N/A
-6%

Customers

Americas and Europe Region
Q1 2026 Year-Over-Year Year-Over-Year(Constant Currency) Sequentially
Net Sales $35 million -6% -10% -13%
Active Customers 78,000 -8% N/A -4%

Americas and Europe Region

Q1 2026

Year-Over-Year

Year-Over-Year(Constant Currency)

Sequentially

Net Sales

$35 million
-6%
-10%
-13%

Active Customers

78,000
-8%
N/A
-4%

Hiya Health

Q1 2026 Year-Over-Year Sequentially
Net Sales $32 million -13% +7%
Active Monthly Subscribers 186,000 -17% +2%

Q1 2026

Year-Over-Year

Sequentially

Net Sales

$32 million
-13%
+7%

Active Monthly Subscribers

186,000
-17%
+2%

Rise Wellness

Q1 2026 Year-Over-Year Sequentially
Net Sales $14 million +741% +143%

Q1 2026

Year-Over-Year

Sequentially

Net Sales

$14 million
+741%
+143%

Balance Sheet

The Company ended the quarter with $163 million in cash and cash equivalents and $14 million of debt. As of April 4, 2026, inventory totaled $99 million, a decrease of approximately $8 million, or -7% compared to balances at year-end 2025. This decrease was driven by strong performance by Rise Wellness, particularly from the fulfillment of orders with key retailers.
The Company did not repurchase any shares during the quarter and has approximately $34 million remaining under the current share repurchase authorization as of the end of the first quarter.

Fiscal Year 2026 Outlook

The Company is reiterating its outlook for fiscal year 2026, as follows:
Fiscal Year 2026 Outlook
Range
Core Nutritional business net sales $720 to $765 million*
Hiya net sales $140 to $155 million
Rise Wellness net sales $65 to $80 million
Consolidated net sales $925 million to $1.0 billion
Net earnings $20 million to $27 million
Diluted EPS $1.11 to $1.45
Adjusted diluted EPS(1) $1.95 to $2.29
Adjusted EBITDA(2) $101 million to $109 million

Fiscal Year 2026 Outlook

Range

Core Nutritional business net sales
$720 to $765 million*
Hiya net sales
$140 to $155 million
Rise Wellness net sales
$65 to $80 million

Consolidated net sales

$925 million to $1.0 billion

Net earnings
$20 million to $27 million
Diluted EPS
$1.11 to $1.45
Adjusted diluted EPS(1)
$1.95 to $2.29
Adjusted EBITDA(2)
$101 million to $109 million
*Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.
*Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.
“Consolidated first quarter operating results reflected meaningful sequential top line improvement, driven by total active customer growth in China in our Core Nutritional business and the fulfillment of Rise Wellness orders. We delivered adjusted EBITDA of $28.4 million and adjusted diluted EPS of $0.61, demonstrating that we are funding the growth of our omnichannel portfolio from a position of financial strength,” said Doug Hekking, Chief Financial Officer. "Our balance sheet remains healthy with $163 million in cash, providing the flexibility to continue executing our strategic priorities. We are also making progress on our technology modernization initiative, which we are funding primarily through repurposing existing resources as well as savings from operational efficiencies, underscoring our commitment to innovation while maintaining fiscal discipline. On the strength of our first quarter results and our visibility into the growth catalysts ahead, we are reaffirming our fiscal 2026 guidance across all metrics."
_________________________
(1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.

Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.
Adjusted EBITDA (non-GAAP) is net earnings (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.
Adjusted diluted earnings per share (non-GAAP) is diluted earnings per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.
Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.
The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”) and investors should not directly compare with or infer relationship from any of the Company’s operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.
Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP)(in thousands)
Quarter ended
April 4,2026 March 29,2025
Net earnings attributable to USANA (GAAP) $ 7,515 $ 9,402
Net (loss) earnings attributable to noncontrolling interest (556 ) (112 )
Net earnings $ 6,959 $ 9,290
Adjustments:
Income taxes $ 8,506 $ 7,449
Interest (income) expense (197 ) (312 )
Depreciation and amortization 5,334 5,790
Amortization of intangible assets - Hiya 4,455 4,455
Earnings before interest, taxes, depreciation, and amortization (EBITDA) $ 25,057 $ 26,672
Add EBITDA adjustments:
Non-cash share-based compensation 3,454 2,880
Transaction, integration and transition costs - Hiya 239 577
Inventory step-up - Hiya 582
Adjusted EBITDA 28,750 30,711
Less: Adjusted EBITDA attributable to noncontrolling interest (387 ) (954 )
Adjusted EBITDA attributable to USANA $ 28,363 $ 29,757

Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP)

(in thousands)

Quarter ended

April 4,2026

March 29,2025

Net earnings attributable to USANA (GAAP)

Net (loss) earnings attributable to noncontrolling interest
(556
)
(112
)

Net earnings

Adjustments:
Income taxes
$
8,506
$
7,449
Interest (income) expense
(197
)
(312
)
Depreciation and amortization
5,334
5,790
Amortization of intangible assets - Hiya
4,455
4,455

Earnings before interest, taxes, depreciation, and amortization (EBITDA)

Add EBITDA adjustments:
Non-cash share-based compensation
3,454
2,880
Transaction, integration and transition costs - Hiya
239
577
Inventory step-up - Hiya
582
Adjusted EBITDA
28,750
30,711
Less: Adjusted EBITDA attributable to noncontrolling interest
(387
)
(954
)

Adjusted EBITDA attributable to USANA

Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)(in thousands, except per share data)
Quarter ended
April 04,2026 March 29,2025
Net earnings attributable to USANA (GAAP) $ 7,515 $ 9,402
Earnings per common share - Diluted (GAAP) $ 0.41 $ 0.49
Weighted Average common shares outstanding - Diluted 18,411 19,085
Adjustment to net earnings:
Transaction, integration and transition costs - Hiya $ 239 $ 577
Inventory step-up - Hiya 582
Amortization of intangible assets - Hiya 4,455 4,455
Adjustments to net earnings attributable to noncontrolling interest (942 ) (1,066 )
Income tax effect of adjustments to net earnings (4 )
Adjusted net earnings attributable to USANA $ 11,267 $ 13,946
Adjusted earnings per common share - Diluted $ 0.61 $ 0.73
Weighted average common shares outstanding - Diluted 18,411 19,085

Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)

(in thousands, except per share data)

Quarter ended

April 04,2026

March 29,2025

Net earnings attributable to USANA (GAAP)
$
7,515
$
9,402

Earnings per common share - Diluted (GAAP)

Weighted Average common shares outstanding - Diluted
18,411
19,085
Adjustment to net earnings:
Transaction, integration and transition costs - Hiya
$
239
$
577
Inventory step-up - Hiya
582
Amortization of intangible assets - Hiya
4,455
4,455
Adjustments to net earnings attributable to noncontrolling interest
(942
)
(1,066
)
Income tax effect of adjustments to net earnings
(4
)
Adjusted net earnings attributable to USANA
$
11,267
$
13,946

Adjusted earnings per common share - Diluted

Weighted average common shares outstanding - Diluted
18,411
19,085

Management Commentary Document and Conference Call

For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, May 6, 2026 at 11:00 AM Eastern Time.Investors may listen to the call by accessing USANA’s website athttp://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “expect,” “enhance,” “drive,” “anticipate,” “intend,” “improve,” “promote,” “should,” “believe,” “continue,” “plan,” “goal,” “opportunity,” “estimate,” “predict,” “may,” “will,” “could,” and “would,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company’s long-term growth; and the statements under the sub-heading “Fiscal Year 2026 Outlook.” Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to Hiya’s ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Rise Wellness’ dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts or such retailers discontinue purchasing and selling Rise Wellness products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict between the United States and Iran; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt the Company’s overall strategic plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability to retain key personnel of Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya’s business with USANA’s business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found atwww.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found atwww.hiyahealth.com. More information on Rise Wellness can be found onwww.risebar.comandwww.proteinpop.com.
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)
Three months ended
April 4,2026 March 29,2025
Net sales $ 250,218 $ 249,539
Cost of sales 59,436 52,445
Gross profit 190,782 197,094
Operating expenses:
Brand Partner incentives 88,654 89,985
Selling, general and administrative 88,254 91,438
Total operating expenses 176,908 181,423
Earnings from operations 13,874 15,671
Other income (expense):
Interest income 437 723
Interest expense (240 ) (411 )
Other, net 1,394 756
Other income (expense), net 1,591 1,068
Earnings before income taxes 15,465 16,739
Income taxes 8,506 7,449
Net earnings 6,959 9,290
Less: Net (loss) earnings attributable to redeemable noncontrolling interest (556 ) (112 )
Net earnings attributable to USANA $ 7,515 $ 9,402
Earnings per common share attributable to USANA
Basic $ 0.41 $ 0.49
Diluted $ 0.41 $ 0.49
Weighted average common shares outstanding
Basic 18,398 19,049
Diluted 18,411 19,085

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three months ended

April 4,2026

March 29,2025

Net sales
$
250,218
$
249,539
Cost of sales
59,436
52,445
Gross profit
190,782
197,094
Operating expenses:
Brand Partner incentives
88,654
89,985
Selling, general and administrative
88,254
91,438
Total operating expenses
176,908
181,423
Earnings from operations
13,874
15,671
Other income (expense):
Interest income
437
723
Interest expense
(240
)
(411
)
Other, net
1,394
756
Other income (expense), net
1,591
1,068
Earnings before income taxes
15,465
16,739
Income taxes
8,506
7,449
Net earnings
6,959
9,290
Less: Net (loss) earnings attributable to redeemable noncontrolling interest
(556
)
(112
)
Net earnings attributable to USANA
$
7,515
$
9,402
Earnings per common share attributable to USANA
Basic
$
0.41
$
0.49
Diluted
$
0.41
$
0.49
Weighted average common shares outstanding
Basic
18,398
19,049
Diluted
18,411
19,085
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)
As ofApril 4,2026 As ofJanuary 3,2026
ASSETS
Current assets
Cash and cash equivalents $ 162,751 $ 158,380
Trade accounts receivable (net of allowance of $141 and $137, respectively) 9,657 4,285
Inventories 96,358 102,608
Prepaid expenses and other current assets 25,467 23,132
Total current assets 294,233 288,405
Property and equipment, net 94,625 94,383
Goodwill 138,127 137,962
Intangible assets, net 128,901 133,151
Deferred tax assets 25,159 27,209
Other assets* 57,921 61,805
Total assets $ 738,966 $ 742,915
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable $ 16,230 $ 17,263
Line of credit 14,000 14,000
Other current liabilities 87,009 97,302
Total current liabilities 117,239 128,565
Deferred tax liabilities 5,057 4,892
Other long-term liabilities 21,884 23,186
Redeemable noncontrolling interest 51,236 53,168
Total stockholders' equity attributable to USANA 543,550 533,104
Total liabilities, redeemable noncontrolling interest, and stockholders' equity $ 738,966 $ 742,915

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

As ofApril 4,2026

As ofJanuary 3,2026

ASSETS

Current assets
Cash and cash equivalents
$
162,751
$
158,380
Trade accounts receivable (net of allowance of $141 and $137, respectively)
9,657
4,285
Inventories
96,358
102,608
Prepaid expenses and other current assets
25,467
23,132

Total current assets

294,233
288,405
Property and equipment, net
94,625
94,383
Goodwill
138,127
137,962
Intangible assets, net
128,901
133,151
Deferred tax assets
25,159
27,209
Other assets*
57,921
61,805

Total assets

$
738,966
$
742,915

LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable
$
16,230
$
17,263
Line of credit
14,000
14,000
Other current liabilities
87,009
97,302

Total current liabilities

117,239
128,565
Deferred tax liabilities
5,057
4,892
Other long-term liabilities
21,884
23,186
Redeemable noncontrolling interest
51,236
53,168
Total stockholders' equity attributable to USANA
543,550
533,104

Total liabilities, redeemable noncontrolling interest, and stockholders' equity

$
738,966
$
742,915
*Includes noncurrent inventories of $3,029 and $4,799 as of 04-Apr-26 and 03-Jan-26, respectively. Total inventories were $99,387 and $107,407 as of 04-Apr-26 and 03-Jan-26, respectively.
*Includes noncurrent inventories of $3,029 and $4,799 as of 04-Apr-26 and 03-Jan-26, respectively. Total inventories were $99,387 and $107,407 as of 04-Apr-26 and 03-Jan-26, respectively.
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIESSALES BY REGION(in thousands)(unaudited)
Quarter ended
April 4,2026 March 29,2025 Changefromprioryear Percentchange Currencyimpact onsales Percentchangeexcludingcurrencyimpact
Core Nutritional:
Asia Pacific
Greater China $ 123,334 49.3 % $ 118,746 47.6 % $ 4,588 3.9 % $ 4,986 (0.3 %)
Southeast Asia Pacific 30,663 12.3 % 35,720 14.3 % (5,057 ) (14.2 %) 1,942 (19.6 %)
North Asia 15,352 6.1 % 18,941 7.6 % (3,589 ) (18.9 %) (160 ) (18.1 %)
Asia Pacific total 169,349 67.7 % 173,407 69.5 % (4,058 ) (2.3 %) 6,768 (6.2 %)
Americas and Europe 35,050 14.0 % 37,417 15.0 % (2,367 ) (6.3 %) 1,323 (9.9 %)
Core Nutritional total 204,399 81.7 % 210,824 84.5 % (6,425 ) (3.0 %) 8,091 (6.9 %)
Hiya 32,150 12.8 % 37,089 14.9 % (4,939 ) (13.3 %) (13.3 %)
Rise 13,669 5.5 % 1,626 0.6 % 12,043 740.7 % 740.7 %
Consolidated total $ 250,218 100.0 % $ 249,539 100.0 % $ 679 0.3 % $ 8,091 (3.0 %)

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

SALES BY REGION

(in thousands)

(unaudited)

Quarter ended

April 4,2026

March 29,2025

Changefromprioryear

Percentchange

Currencyimpact onsales

Percentchangeexcludingcurrencyimpact

Core Nutritional:
Asia Pacific
Greater China
$
123,334
49.3
%
$
118,746
47.6
%
$
4,588
3.9
%
$
4,986
(0.3
%)
Southeast Asia Pacific
30,663
12.3
%
35,720
14.3
%
(5,057
)
(14.2
%)
1,942
(19.6
%)
North Asia
15,352
6.1
%
18,941
7.6
%
(3,589
)
(18.9
%)
(160
)
(18.1
%)
Asia Pacific total
169,349
67.7
%
173,407
69.5
%
(4,058
)
(2.3
%)
6,768
(6.2
%)
Americas and Europe
35,050
14.0
%
37,417
15.0
%
(2,367
)
(6.3
%)
1,323
(9.9
%)
Core Nutritional total
204,399
81.7
%
210,824
84.5
%
(6,425
)
(3.0
%)
8,091
(6.9
%)
Hiya
32,150
12.8
%
37,089
14.9
%
(4,939
)
(13.3
%)
(13.3
%)
Rise
13,669
5.5
%
1,626
0.6
%
12,043
740.7
%
740.7
%
Consolidated total
$
250,218
100.0
%
$
249,539
100.0
%
$
679
0.3
%
$
8,091
(3.0
%)
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIESCORE NUTRITIONAL ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION(unaudited)
Core Nutritional Active Brand Partners by Region(1)
(unaudited)
As ofApril 4, 2026 As ofMarch 29, 2025
Asia Pacific
Greater China 62,000 37.1 % 65,000 35.3 %
Southeast Asia Pacific 43,000 25.7 % 48,000 26.1 %
North Asia 25,000 15.0 % 33,000 17.9 %
Asia Pacific Total 130,000 77.8 % 146,000 79.3 %
Americas and Europe 37,000 22.2 % 38,000 20.7 %
167,000 100.0 % 184,000 100.0 %

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CORE NUTRITIONAL ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION

(unaudited)

Core Nutritional Active Brand Partners by Region(1)

(unaudited)

As ofApril 4, 2026

As ofMarch 29, 2025

Asia Pacific
Greater China
62,000
37.1
%
65,000
35.3
%
Southeast Asia Pacific
43,000
25.7
%
48,000
26.1
%
North Asia
25,000
15.0
%
33,000
17.9
%
Asia Pacific Total
130,000
77.8
%
146,000
79.3
%
Americas and Europe
37,000
22.2
%
38,000
20.7
%
167,000
100.0
%
184,000
100.0
%
Core Nutritional Active Preferred Customers by Region(2)
(unaudited)
As ofApril 4, 2026 As ofMarch 29, 2025
Asia Pacific
Greater China 173,000 73.0 % 189,000 68.7 %
Southeast Asia Pacific 16,000 6.7 % 27,000 9.8 %
North Asia 7,000 3.0 % 12,000 4.4 %
Asia Pacific Total 196,000 82.7 % 228,000 82.9 %
Americas and Europe 41,000 17.3 % 47,000 17.1 %
237,000 100.0 % 275,000 100.0 %

Core Nutritional Active Preferred Customers by Region(2)

(unaudited)

As ofApril 4, 2026

As ofMarch 29, 2025

Asia Pacific
Greater China
173,000
73.0
%
189,000
68.7
%
Southeast Asia Pacific
16,000
6.7
%
27,000
9.8
%
North Asia
7,000
3.0
%
12,000
4.4
%
Asia Pacific Total
196,000
82.7
%
228,000
82.9
%
Americas and Europe
41,000
17.3
%
47,000
17.1
%
237,000
100.0
%
275,000
100.0
%
______________________________
(1) Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.
(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

______________________________

Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.
Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIESOPERATING RESULTS AS A PERCENTAGE OF NET SALES(unaudited)
Quarter ended
April 4, 2026 March 29, 2025
CoreNutritional Hiya Rise Consolidated CoreNutritional Hiya Rise Consolidated
Net sales 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Cost of sales 18.0% 31.1% 92.9% 23.8% 17.7% 38.0% 65.1% 21.0%
Gross profit 82.0% 68.9% 7.1% 76.2% 82.3% 62.0% 34.9% 79.0%
Operating expenses:
Brand Partner incentives 43.4% —% 35.4% 42.7% —% —% 36.1%
Selling, general and administrative 29.7% 77.0% 20.0% 35.3% 31.6% 63.4% 79.2% 36.6%
Total operating expenses 73.1% 77.0% 20.0% 70.7% 74.3% 63.4% 79.2% 72.7%
Earnings (loss) from operations 8.9% (8.1)% (12.9)% 5.5% 8.0% (1.4)% (44.3)% 6.3%
Amortization of acquired intangible assets —% 13.9% 1.5% 1.9% —% 12.0% 13.0% 1.9%

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

OPERATING RESULTS AS A PERCENTAGE OF NET SALES

(unaudited)

Quarter ended

April 4, 2026

March 29, 2025

CoreNutritional

Hiya

Rise

Consolidated

CoreNutritional

Hiya

Rise

Consolidated

Net sales
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Cost of sales
18.0%
31.1%
92.9%
17.7%
38.0%
65.1%
Gross profit
82.0%
68.9%
7.1%
82.3%
62.0%
34.9%
Operating expenses:
Brand Partner incentives
43.4%
—%
42.7%
—%
—%
Selling, general and administrative
29.7%
77.0%
20.0%
31.6%
63.4%
79.2%
Total operating expenses
73.1%
77.0%
20.0%
74.3%
63.4%
79.2%
Earnings (loss) from operations
8.9%
(8.1)%
(12.9)%
8.0%
(1.4)%
(44.3)%
Amortization of acquired intangible assets
—%
13.9%
1.5%
—%
12.0%
13.0%
Last updated: May 5, 2026